Intensified neoadjuvant treatment sequence with chemotherapy followed by SBRT for a borderline resectable pancreatic cancer: a plea for prospective evaluation.
Laura Mans(Université Libre de Bruxelles), Jean–Luc Van Laethem, Jean Closset(Erasmus Hospital), Laurine Verset(Université Libre de Bruxelles), Christelle Bouchart(Université Libre de Bruxelles), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Martina Pezzullo
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)
March 30, 2021
Cited by 0
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
|Journal of Crohn s and Colitis|2013|669
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299
Pancreatic-fluid collections: a randomized controlled trial regarding stent removal after endoscopic transmural drainage
|Gastrointestinal Endoscopy|2007|286